Ocugen signs binding term sheet to license OCU400 gene therapy in Korea; up to $11M upfront & milestones

Ocugen, Inc.

Upfront license fees and near-term development milestones up to $11M.
Sales milestones of $1M per $15M net sales in Korea (or $150M+ in first 10 years).
Royalty of 25% on net sales; Ocugen to manufacture and supply OCU400.
Estimated 15,000 RP patients in Korea; definitive agreement expected within 60 days.
OCU400 in Phase 3 with target BLA filing mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.